Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Charter Communications Inc (CHTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Charter Communications Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Charter Communications Inc trades at $133.51 (market cap $16.97B). The key difference: Charter Communications Inc is far larger — about 3.8× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CHTR | |
|---|---|---|
Market Cap | $4.49B | $16.97B |
Sector | Health | Media |
52-Week High | $28.06 | $411.66 |
52-Week Low | $20.06 | $125.54 |
Enterprise Value | $3.69B | $113.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Charter Communications (CHTR) trades at $138.02, up 0.6% on the day, with a bearish technical signal but deeply discounted valuation metrics including a P/E of 3.66 and EV/EBITDA of 5.32. Recent news highlights a potential mobile partnership with SpaceX, driving significant pre-market gains, while financials show stable revenue near $54.8B and improving operating cash flow to $16.08B in 2025.
The stock presents a high-risk, high-reward opportunity, with a consensus price target of $214 suggesting 55% upside, but faces headwinds from high debt, competitive pressures, and inconsistent earnings beats. Investor sentiment is mixed, balancing low valuation against operational challenges and leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
